(29 days)
P950037/S66, P950037/S69
No
The document describes the device's functionality in terms of detecting specific, predefined cardiac arrhythmias based on subcutaneous electrocardiogram (SECG) data. It mentions "detecting a number of arrhythmias" and "designed to detect and trigger automatic recording of certain cardiac arrhythmias," but the language focuses on rule-based detection rather than adaptive learning or pattern recognition characteristic of AI/ML. There is no mention of AI, ML, deep learning, training data, or performance metrics typically associated with AI/ML models. The performance studies described are focused on electrical, wireless, and system verification testing, not the evaluation of an AI/ML algorithm's performance.
No.
The device description clearly states its purpose is to "detect" and aid in the "diagnosis of cardiac arrhythmias," and it "reports the recorded episodes and related statistical data," rather than providing any form of therapy.
Yes
The device "BioMonitor 2 is intended to aid in the diagnosis of cardiac arrhythmias that might otherwise go undetected." This explicitly states its diagnostic purpose.
No
The device description explicitly states that the BioMonitor 2 "senses subcutaneous electrocardiograms (SECG) using two integrated electrodes," indicating the presence of hardware components for data acquisition.
Based on the provided information, the BioMonitor 2 is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for diagnostic purposes.
- BioMonitor 2 Function: The BioMonitor 2 senses subcutaneous electrocardiograms (SECG) directly from the patient's body using integrated electrodes. It analyzes these electrical signals to detect cardiac arrhythmias. It does not process specimens taken from the body.
- Intended Use: The intended use is to detect cardiac arrhythmias in patients, aiding in the diagnosis of these conditions. This is done through direct physiological monitoring, not through the analysis of biological samples.
Therefore, the BioMonitor 2 falls under the category of a medical device that performs physiological monitoring and analysis, but it does not meet the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The BioMonitor 2 is indicated to detect the following cardiac arrhythmias:
- Atrial fibrillation,
- Bradycardia,
- Sudden rate drop.
- High ventricular rate (HVR),
- Asystole.
The BioMonitor 2 is indicated for:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- Patients who experience transient symptoms that may suggest a cardiac arrhythmia
- The device has not been tested for and it is not intended for pediatric use
Product codes (comma separated list FDA assigned to the subject device)
MXD
Device Description
The BioMonitor 2 senses subcutaneous electrocardiograms (SECG) using two integrated electrodes and has the capability of detecting a number of arrhythmias. The BioMonitor 2 uses BIOTRONIK's Home Monitoring to send recorded SECG and statistics to the Home Monitoring Service Center (P950037/S66, dated November 21, 2008; and P950037/S69, dated March 23, 2009) for further analysis. BioMonitor 2 is intended to aid in the diagnosis of cardiac arrhythmias that might otherwise go undetected.
BioMonitor 2 is designed to detect and trigger automatic recording of certain cardiac arrhythmias; these arrhythmias can be classified as follows:
- atrial fibrillation,
- bradycardia,
- sudden rate drop,
- high ventricular rate (HVR),
- asystole.
Patients can also manually trigger recording of the cardiac information by use of the Remote Assistant.
The memory capacity of BioMonitor 2 is such that the device can record at least 66 minutes of subcutaneous electrocardiograms (SECG). The device automatically stores a maximum of 55 separately recorded SECG-episodes of 40 seconds each (60 seconds maximum), and a maximum of 4 patient triggered SECG-episodes of 7.5 minutes. The BioMonitor 2 reports the recorded episodes and related statistical data through the physician's programmer and BIOTRONIK's Home Monitoring.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
The device has not been tested for and it is not intended for pediatric use
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following performance data were provided in support of the substantial equivalence determination.
To demonstrate that the modified BioMonitor 2 meets the same performance criteria, the following tests were conducted using the same test methods and acceptance criteria as for the predicate device.
- Compatibility testing
- Wireless communication user testing
- Module electrical tests
- Device electrical tests
- System verification testing
- Software release testing
- Product level validation testing
- Process validation/verification for manufacturing changes.
No clinical testing was deemed necessary or completed in the premarket notification submission for a determination of substantial equivalence.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
0
Public Health Service
Image /page/0/Picture/2 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is a stylized image of three faces in profile, stacked on top of each other.
March 31, 2017
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Biotronik, Inc Jon Brumbaugh Vice President, Regulatory Affairs and Compliance 6024 Jean Road Lake Oswego, Oregon 97035
Re: K170628
Trade/Device Name: BioMonitor 2 Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector and Alarm (Including ST-Segment Measurement and Alarm) Regulatory Class: Class II Product Code: MXD Dated: March 1, 2017 Received: March 2, 2017
Dear Jon Brumbaugh:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
1
Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Muda Yellm
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K170628
Device Name BioMonitor 2
Indications for Use (Describe)
The BioMonitor 2 is indicated to detect the following cardiac arrhythmias:
- · Atrial fibrillation,
- · Bradycardia,
- · Sudden rate drop.
- · High ventricular rate (HVR),
- Asystole.
The BioMonitor 2 is indicated for:
- · Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- · Patients who experience transient symptoms that may suggest a cardiac arrhythmia
- · The device has not been tested for and it is not intended for pediatric use
| Type of Use (Select one or both, as applicable) | |
|---|---|
|X Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
1. Submitter
BIOTRONIK 6024 SW Jean Road Lake Oswego, OR 97035 Phone: (888) 345-0374 Fax: 503-451-8519
Contact Person: Jon Brumbaugh
Date Prepared: March 1, 2017
2. Device
| Name of Device | BioMonitor 2 |
|---|---|
| Common or Usual | |
| Name | Insertable Cardiac Monitor |
| Classification Name | Arrhythmia detector and alarm (including ST-segment measurement and |
| alarm) | |
| Classification | Class II (21 CFR 870.1025) |
| Product Code | MXD |
3. Predicate Devices
- BIOTRONIK BioMonitor 2 (K152995, cleared April 11, 2016) o
4. Device Description
The BioMonitor 2 senses subcutaneous electrocardiograms (SECG) using two integrated electrodes and has the capability of detecting a number of arrhythmias. The BioMonitor 2 uses BIOTRONIK's Home Monitoring to send recorded SECG and statistics to the Home Monitoring Service Center (P950037/S66, dated November 21, 2008; and P950037/S69, dated March 23, 2009) for further analysis. BioMonitor 2 is intended to aid in the diagnosis of cardiac arrhythmias that might otherwise go undetected.
BioMonitor 2 is designed to detect and trigger automatic recording of certain cardiac arrhythmias; these arrhythmias can be classified as follows:
- . atrial fibrillation,
- . bradycardia,
- sudden rate drop, .
- high ventricular rate (HVR),
- asystole.
Patients can also manually trigger recording of the cardiac information by use of the Remote Assistant.
The memory capacity of BioMonitor 2 is such that the device can record at least 66 minutes of subcutaneous electrocardiograms (SECG). The device automatically stores a maximum of 55 separately recorded SECG-episodes of 40 seconds each (60 seconds maximum), and a maximum of 4 patient triggered SECG-episodes of 7.5 minutes. The BioMonitor 2 reports the recorded episodes and related statistical data through the physician's programmer and BIOTRONIK's Home Monitoring .
4
5. Indications for Use
The BioMonitor 2 is indicated to detect the following cardiac arrhythmias:
- Atrial fibrillation. ●
- Bradycardia, ●
- Sudden rate drop,
- High ventricular rate (HVR), ●
- Asystole.
The BioMonitor 2 is indicated for:
- Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias ●
- Patients who experience transient symptoms that may suggest a cardiac arrhythmia
- The device has not been tested for and it is not intended for pediatric use o
6. Comparison of Technological Characteristics with the Predicate Device
The technological principles of the subject and predicate device are the differences represent minor modifications to the currently marketed BioMonitor 2 as follows:
- . A modified radio frequency integrated circuit
- o Manufacturing changes with no effect on performance criteria
7. Performance Data
The following performance data were provided in support of the substantial equivalence determination.
To demonstrate that the modified BioMonitor 2 meets the same performance criteria, the following tests were conducted using the same test methods and acceptance criteria as for the predicate device.
- Compatibility testing
- . Wireless communication user testing
- Module electrical tests ●
- Device electrical tests ●
- System verification testing
- Software release testing
- Product level validation testing ●
- Process validation/verification for manufacturing changes. ●
No clinical testing was deemed necessary or completed in the premarket notification submission for a determination of substantial equivalence.
8. Conclusions
The subject device results from minor modifications to the predicate device. The performance testing demonstrates that the subject device meet the same functional acceptance criteria for the same intended use.